NO20023670L - Antistoff med spesifisitet for colonkreft - Google Patents

Antistoff med spesifisitet for colonkreft

Info

Publication number
NO20023670L
NO20023670L NO20023670A NO20023670A NO20023670L NO 20023670 L NO20023670 L NO 20023670L NO 20023670 A NO20023670 A NO 20023670A NO 20023670 A NO20023670 A NO 20023670A NO 20023670 L NO20023670 L NO 20023670L
Authority
NO
Norway
Prior art keywords
specificity
antibody
colon cancer
colon
cancer
Prior art date
Application number
NO20023670A
Other languages
English (en)
Other versions
NO20023670D0 (no
Inventor
Thomas Brodin
Pia J Karlstroem
Bo H K Nilson
Lennart G Ohlsson
M Jesper Tordsson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of NO20023670D0 publication Critical patent/NO20023670D0/no
Publication of NO20023670L publication Critical patent/NO20023670L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20023670A 2000-02-24 2002-08-02 Antistoff med spesifisitet for colonkreft NO20023670L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0000597A SE0000597D0 (sv) 2000-02-24 2000-02-24 Novel antibody
PCT/SE2001/000395 WO2001062286A1 (en) 2000-02-24 2001-02-23 Novel antibody with specificity for colon cancer

Publications (2)

Publication Number Publication Date
NO20023670D0 NO20023670D0 (no) 2002-08-02
NO20023670L true NO20023670L (no) 2002-08-23

Family

ID=20278567

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023670A NO20023670L (no) 2000-02-24 2002-08-02 Antistoff med spesifisitet for colonkreft

Country Status (22)

Country Link
US (1) US7425623B2 (no)
EP (1) EP1257291A1 (no)
JP (1) JP2003523213A (no)
KR (1) KR20020079888A (no)
CN (1) CN1406136A (no)
AU (1) AU775876B2 (no)
BR (1) BR0108609A (no)
CA (1) CA2400661A1 (no)
EE (1) EE200200473A (no)
HK (1) HK1052648A1 (no)
HU (1) HUP0300007A3 (no)
IL (1) IL151325A0 (no)
MX (1) MXPA02008315A (no)
NO (1) NO20023670L (no)
NZ (1) NZ520523A (no)
PL (1) PL356386A1 (no)
RU (1) RU2268068C2 (no)
SE (1) SE0000597D0 (no)
SK (1) SK11982002A3 (no)
WO (1) WO2001062286A1 (no)
YU (1) YU63702A (no)
ZA (1) ZA200206039B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450692A1 (en) * 2001-06-12 2003-01-30 Kyogo Itoh Tumor antigen
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
CN1303105C (zh) * 2003-12-08 2007-03-07 陈志南 抗人大肠癌单克隆抗体CAb—2轻、重链可变区基因及其应用
WO2007146172A2 (en) * 2006-06-07 2007-12-21 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2048241B1 (en) * 2007-10-08 2012-07-25 Sividon Diagnostics GmbH Method employing GAPDH as molecular markers for cancer prognosis
DK2245063T3 (en) * 2007-12-18 2015-12-07 Bioalliance Cv Antibodies that recognize carbohydrate AN EPITOPE ON CD-43 AND CEA expressed CANCER CELLS AND PRACTICES BY WHICH THEY USED
WO2010023917A1 (ja) * 2008-09-01 2010-03-04 国立大学法人名古屋大学 抗がん剤の作用増強剤及びその利用、並びにがん患者の予後推定用バイオマーカー及びその利用
FR2945952B1 (fr) * 2009-05-27 2013-10-04 Univ Claude Bernard Lyon Anticorps anti-ck8 pour utilisation comme medicament.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798257A (en) * 1990-07-09 1998-08-25 Research Corporation Technologies, Inc. Nucleic acid encoding human MTS-1 protein
US5994088A (en) * 1991-03-08 1999-11-30 Board Of Trustees Of The University Of Illinois Methods and reagents for preparing and using immunological agents specific for P-glycoprotein
EP0656788B1 (en) * 1992-08-07 2006-10-18 Pharmexa Inc. Hla binding peptides and their uses
US5972643A (en) * 1994-06-17 1999-10-26 Fred Hutchinson Cancer Research Center Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
IL125073A0 (en) * 1996-01-08 1999-01-26 Genentech Inc Wsx receptor and ligands
WO1998003411A1 (fr) 1996-07-18 1998-01-29 Montania Bouchon avec recipient auxiliaire et procede de realisation
DE69718341T2 (de) * 1996-10-08 2003-10-30 Bisys B V U Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
SE9700291D0 (sv) * 1997-01-31 1997-01-31 Pharmacia & Upjohn Ab Selection method and prodcts resulting therefrom
CA2288600C (en) * 1997-05-02 2010-06-01 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
WO1999010485A1 (en) * 1997-08-29 1999-03-04 Selective Genetics, Inc. Methods using phage display for selecting internalizing ligands for gene delivery
DE19739525A1 (de) * 1997-09-09 1999-09-30 Heinrich Abbrederis Die Vorrichtung T.C.Reinigungskopf ermöglicht die Reinigung, Schmierung und Konservierung von Ketten im eingebauten und ausgebauten Zustand unter minimalen Platzverhältnissen
EP0934953A2 (en) * 1997-12-03 1999-08-11 Boehringer Mannheim Corporation Complex specific antibodies, method of preparation and uses thereof
AU770952B2 (en) * 1999-03-01 2004-03-11 Genentech Inc. Antibodies for cancer therapy and diagnosis

Also Published As

Publication number Publication date
HUP0300007A2 (en) 2003-05-28
EP1257291A1 (en) 2002-11-20
JP2003523213A (ja) 2003-08-05
HUP0300007A3 (en) 2005-11-28
IL151325A0 (en) 2003-04-10
CA2400661A1 (en) 2001-08-30
PL356386A1 (en) 2004-06-28
CN1406136A (zh) 2003-03-26
AU3629401A (en) 2001-09-03
RU2002125386A (ru) 2004-03-20
NO20023670D0 (no) 2002-08-02
WO2001062286A1 (en) 2001-08-30
BR0108609A (pt) 2002-11-19
SE0000597D0 (sv) 2000-02-24
SK11982002A3 (sk) 2003-03-04
MXPA02008315A (es) 2002-12-09
AU775876B2 (en) 2004-08-19
US20030176661A1 (en) 2003-09-18
EE200200473A (et) 2004-02-16
RU2268068C2 (ru) 2006-01-20
KR20020079888A (ko) 2002-10-19
YU63702A (sh) 2006-01-16
US7425623B2 (en) 2008-09-16
NZ520523A (en) 2004-08-27
ZA200206039B (en) 2003-07-29
HK1052648A1 (zh) 2003-09-26

Similar Documents

Publication Publication Date Title
LTC2371392I2 (lt) Kalicheamicino darinio-nešiklio konjugatai
NO20031642L (no) Humaniserte anti-LT-ß-R-antistoff
DE60123142D1 (de) Biosensor
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
DE60108010D1 (de) Toner
NO20004554L (no) Sand-detektor
MA25850A1 (fr) Conjugues de pro-parfums photolabiles.
NO20026121D0 (no) Streptokokkantigener
DE60129568D1 (de) Ferritmaterial
DE50111872D1 (de) Durchflussmesser
DE60121132D1 (de) Vollsperrendes momentabhängiges differential
EE200300569A (et) CD44v6-spetsiifilised antikehad
DE60102861D1 (de) Toner
NO20023670L (no) Antistoff med spesifisitet for colonkreft
DE10135354B8 (de) Gleitsattelscheibenbremse
DE60136030D1 (de) Synchronisierer
DE60108933D1 (de) Synchronisiereinrichtung
FI20011055A (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
ITRE20010085A0 (it) Indumento intimo
FI20001827A (fi) Sulatusuunin pohjarakenne
ITPD20000192A0 (it) Anticorpi policlonali
DE60008767D1 (de) Induktive Heizwalze
DE60109079D1 (de) Trinkbehälter
FR2812712B1 (fr) Doublure pour abat-jour
DE60035197D1 (de) Fahrbahnoberfläche-rauheitsmessvorrichtung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application